GLP-1/GIP candidate delivers 22% placebo-adjusted weight loss while less-frequent dosing shows potential for maintaining results Viking Therapeutics (VKTX) announced positive ...
Shares rise as biotech firm begins Phase 1 study of experimental therapy VK3019 Shares of Viking Therapeutics (VKTX) moved higher ...
VK2735 advances across injectable and oral formats as company strengthens position in weight-loss therapeutics Viking Therapeutics (VKTX) reported strong first-quarter ...
Late-stage pipeline progress and market momentum position the biotech as a key emerging player Viking Therapeutics (VKTX) is entering a ...
Company advances VKTX program as competition intensifies in the rapidly expanding weight-loss market Viking Therapeutics (VKTX) announced Wednesday that it ...
Strong weight reduction overshadowed by concerns over side effects Viking Therapeutics (VKTX) shares plummeted nearly 45% on Tuesday after the ...
